|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S.B. 333 VETOES
|
|
|
|
|
|
|
|
|
multidisciplinary consultation team to assist in the interpretation of
prescription monitoring data; requiring dispensers to submit electronically
certain information to the Program except in certain circumstances; prohibiting
the Board and the Secretary from charging a fee or imposing an assessment on
certain persons for certain purposes; making prescription monitoring data
confidential and privileged and not subject to certain means of legal compulsion
except under certain circumstances; authorizing certain agencies and persons to
obtain access to prescription monitoring data under certain circumstances;
establishing immunity from civil liability for certain agencies and persons
relating to the operation and use of the Program; providing for education and
training relating to the Program; establishing penalties for violations of the
requirements of the Program; defining certain terms; providing that
implementation of the Program is contingent on the Board obtaining certain
federal grant money federal, State, or private funds; prohibiting the Program
from collecting prescription monitoring data before a certain date; and generally
relating to the creation and operation of the Prescription Drug Monitoring
Program.
BY adding to
Article - Health — General
Section 21-2A-01 through 21-2A-09, inclusive, to be under the new subtitle
"Subtitle 2A. Prescription Drug Monitoring Program"
Annotated Code of Maryland
(2005 Replacement Volume and 2005 Supplement)
Preamble
WHEREAS, Thousands of Marylanders suffer from chronic pain and other
conditions that make access to pain medications and other pharmaceutical therapies
necessary and beneficial; and
WHEREAS, Increasing numbers of Maryland adults and adolescents are
engaging in prescription drug abuse and diversion to the detriment of their health
and welfare; and
WHEREAS, Maryland should have a Prescription Drug Monitoring Program
that supports the lawful use of controlled substances without interfering with
legitimate professional practice and patient care; and
WHEREAS, A Prescription Drug Monitoring Program should assist health care
professionals and law enforcement professionals in the identification, treatment, and
prevention of prescription drug abuse and in the identification and investigation of
unlawful prescription drug diversion; and
WHEREAS, Data concerning monitored prescription drugs under a Prescription
Drug Monitoring Program would be available for research purposes, including
research about the effects of the Prescription Drug Monitoring Program itself; now,
therefore,
|
|
|
|
|
|
|
|
|
|
- 3020 -
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
